Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12 Week, Double-Blind, Randomized, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension.

Next Previous
Trial Profile

A 12 Week, Double-Blind, Randomized, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/hydrochlorothiazide (Primary) ; Aliskiren
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms ACQUIRE
  • Sponsors Novartis

Most Recent Events

  • 01 Aug 2012 Results published in the Journal of Clinical Hypertension (Greenwich).
  • 22 Jan 2010 Actual end date (April 2009) added as reported by ClinicalTrials.gov.
  • 22 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top